drugset
drugset / Trial / NCT04081844

A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.

NCT04081844 ↗

Phase 1 Completed 31 enrolled Hanmi Pharmaceutical Company Limited
SequentialOpen-labelTreatment

Summary

An Open-label, Multiple-dose, Fixed-sequence, 3-Period Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions between HGP0904, HGP0608 and HCP1306 in Healthy Male Subjects

Timeline

Start
2018-05-03
Primary completion
2018-06-28
Completion
2018-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg —
Subject Ezetimibe Unknown 10 mg —
Subject Losartan Other / unclassified 100 mg —
Subject Rosuvastatin Small molecule 20 mg —

Indications

No indication recorded.